Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk.
Kausik K Ray, Nicholas Clarke, Peter Thornton et al.
✦ AI-curated · Sources linked
In 30 seconds
This double-blind, randomised Phase 1b trial assessed oral NLRP3 inhibition with ruvonoflast in adults with elevated hsCRP, obesity, and additional cardiovascular risk factors. Among 63 participants, ruvonoflast 225 mg twice daily reduced hsCRP more than placebo at Day 28: geometric least-squares mean reductions were 82.2% (95% CI: 75.9%-86.8%) and 37.2% (95% CI: 7.0%-57.6%), respectively. Interleukin-6 and fibrinogen also fell more with treatment. hsCRP returned to baseline after treatment stopped; four participants receiving ruvonoflast discontinued because of transient, reversible adverse events.
Key findings
- At Day 28, hsCRP fell by 82.2% (95% CI: 75.9%-86.8%) with ruvonoflast and 37.2% (95% CI: 7.0%-57.6%) with placebo.
- Between-group hsCRP differences favored ruvonoflast from Day 3 onward (P ≤ 0.001); hsCRP returned to baseline 7 days after treatment discontinuation.
- Interleukin-6 and fibrinogen were significantly lower with ruvonoflast than placebo at Day 28 (P < 0.001).
- Four (10%) ruvonoflast-treated participants discontinued because of transient, reversible adverse events, compared with none receiving placebo.
Why it matters
The trial provides early clinical evidence that oral NLRP3 inhibition can reduce hsCRP and other inflammatory biomarkers in people with residual inflammatory risk and elevated cardiovascular risk. These biomarker changes support further study of the pathway, but the findings do not establish effects on cardiovascular events or long-term clinical outcomes.
What to keep in mind
This was a small Phase 1b trial with short follow-up; it assessed inflammatory biomarkers rather than cardiovascular outcomes.